Evidence map›Paper›PMID 39586949›Full record

ArticleJournal of general internal medicine2025

Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.

Riley Shearer, Honora Englander, Hildi Hagedorn, Adetayo Fawole, JoAn Laes, Hope Titus, Alisa Patten, Emily Oot, Noa Appleton, Amy Fitzpatrick and 11 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Riley ShearerUniversity of Minnesota School of Public Health, Minneapolis, MN, USA.
Honora EnglanderOregon Health and Science University, Portland, OR, USA.
Hildi HagedornMinneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA.
Adetayo FawoleNew York University Grossman School of Medicine, New York, NY, USA.
JoAn LaesHennepin Healthcare Research Institute, Minneapolis, MN, USA.
Hope TitusOregon Health and Science University, Portland, OR, USA.
Alisa PattenOregon Health and Science University, Portland, OR, USA.
Emily OotBoston University, Boston, MA, USA.
Noa AppletonNew York University Grossman School of Medicine, New York, NY, USA.
Amy FitzpatrickBoston Medical Center and the Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Roxanne KibbenHennepin Healthcare Research Institute, Minneapolis, MN, USA.
Jasmine FernandoNew York University Grossman School of Medicine, New York, NY, USA.
Jennifer McNeelyNew York University Grossman School of Medicine, New York, NY, USA.
Dave GustafsonUniversity of Wisconsin, Madison, WI, USA.
Noa KrawczykNew York University Grossman School of Medicine, New York, NY, USA.
Zoe WeinsteinBoston Medical Center and the Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Paulette BaukolHennepin Healthcare Research Institute, Minneapolis, MN, USA.
Udi GhitzaNational Institute On Drug Abuse, North Bethesda, MD, USA.
Tracy SieglerUniversity of Wisconsin, Madison, WI, USA.
Gavin BartHennepin Healthcare, Minneapolis, MN, USA.
Angela BazziHerbert Wertheim School of Public Health, University of California San Diego, La Jolla, CA, USA. abazzi@health.ucsd.edu.ORCID 0000-0001-6828-1919

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Suicide Prediction and Prevention for People at Risk for Opioid Use DisorderUG1DA040316 · NIDA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI GAVIN BART · 2015 to 2026
$42.2M
TRANSCRANIAL MAGNETIC STIMULATION FOR THE TREATMENT OF METHAMPHETAMINE/COCAINE USE DISORDER (CTN-0108). 9/21/2020-7/17/2023. N01DA-19-2250. TASK ORDER75N95019D00013 · NIDA · THE EMMES COMPANY, LLC · PI MCCORMACK, JENNIFER · 2019 to 2022
$32.8M
PROCESS DEVELOPMENT OF TELACEBEC FOR TUBERCULOSIS75N95024D00012 · NIDA · MIDWEST RESEARCH INSTITUTE · PI SLADE, DESMOND · 2024 to 2025
$742k
Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System TouchpointsK01DA055758 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Noa Krawczyk · 2023 to 2026
$722k
Characteristics and outcomes for hospitalized patients with methamphetamine and opioid co-use: Identifying opportunities for hospital-based addiction services tailored to co-useF30DA057775 · NIDA · UNIVERSITY OF MINNESOTA · PI Riley Shearer · 2023 to 2026
$171k
SCIENTIFIC, OPERATIONS, AND ADMINISTRATIVE RESOURCES (SOAR) TO NIH.75N95021D00012 · NIDA · KELLY SERVICES, INC. · PI SPROSE, SARA · 2021 to 2021
$57k
CLC NIH HHS 75N90019D00013NIDA NIH HHS 75N95021D00012NIDA NIH HHS 75N95021D00013NIDA NIH HHS 75N95024D00012NIDA NIH HHS F30 DA057775NIDA NIH HHS F30DA057775NIDA NIH HHS K01 DA055758NIDA NIH HHS K01DA055758NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA040316NIDA NIH HHS UG1DA040316NIEHS NIH HHS 75N96020D00012NIH HHS 75N95019D00013NIH HHS Contract No. 75N95020D00012ORFDO NIH HHS 75N99019D00013ORFDO NIH HHS 75N99020D00012
6 · The paper itself

Abstract

backgroundIndividuals with opioid use disorder have high rates of hospital admissions, which represent a critical opportunity to engage patients and initiate medications for opioid use disorder (MOUD). However, few patients receive MOUD and, even if MOUD is initiated in the hospital, patients may encounter barriers to continuing MOUD in the community.

objectiveDescribe hospital providers' experiences and perspectives to inform initiatives and policies that support hospital-based MOUD initiation and continuation in community treatment programs.

designAs part of a broader implementation study focused on inpatient MOUD (NCT#04921787), we conducted semi-structured interviews with hospital providers.

participantsFifty-seven hospital providers from 12 community hospitals. APPROACH: Thematic analysis examined an emergent topic on challenges transitioning patients to outpatient MOUD treatment and related impacts on MOUD initiation by inpatient providers. KEY

resultsParticipants described structural barriers to transitioning hospitalized patients to continuing outpatient MOUD including (a) limited outpatient buprenorphine prescriber availability, (b) the siloed nature of addiction treatment, and (c) long wait times. As a result of observing these structural barriers, participants experienced a sense of futility that deterred them from initiating MOUD. Participants proposed strategies that could better support these patient transitions, including developing partnerships between hospitals and outpatient addiction treatment and supporting in-reach services from community providers.

conclusionsWe identified concerns about inadequate and inaccessible community-based care and transition pathways that discouraged hospital providers from prescribing MOUD. As hospital-based opioid treatment models continue to expand, programmatic and policy strategies to support inpatient transitions to outpatient addiction treatment are needed. NCT TRIAL NUMBER: 04921787.

Indexed as

Attitude of Health PersonnelOpiate Substitution TreatmentOpioid-Related DisordersPatient DischargeAdultBuprenorphineFemaleHumansInpatientsMaleMiddle AgedBuprenorphineCare transitionsHospital addiction medicineImplementationMedications for opioid use disorder

Identifiers

PMID39586949
PMCPMC12463795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.